Evidence map›Paper›PMID 37389439›Full record

ArticlemBio2023

Optimized quantification of intra-host viral diversity in SARS-CoV-2 and influenza virus sequence data.

A E Roder, K E E Johnson, M Knoll, M Khalfan, B Wang, S Schultz-Cherry, S Banakis, A Kreitman, C Mederos, J-H Youn and 11 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Intra-host diversity of proviral FeLV and clinical outcomes.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Dispersal of influenza virus populations within the respiratory tract shapes their evolutionary potential.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. CD4Science advances · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 2 countries.

A E Roder *Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH , Bethesda, Maryland, USA.
K E E Johnson *Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH , Bethesda, Maryland, USA.ORCID 0000-0002-9226-0672
M Knoll *Department of Biology, Center for Genomics and Systems Biology, New York University , New York, New York, USA.
M KhalfanDepartment of Biology, Center for Genomics and Systems Biology, New York University , New York, New York, USA.
B WangDepartment of Biology, Center for Genomics and Systems Biology, New York University , New York, New York, USA.
S Schultz-CherryDepartment of Infectious Diseases, St Jude Children Research Hospital , Memphis, Tennessee, USA.ORCID 0000-0002-2021-727X
S BanakisSystems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH , Bethesda, Maryland, USA.
A KreitmanSystems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH , Bethesda, Maryland, USA.
C MederosSystems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH , Bethesda, Maryland, USA.
J-H YounDepartment of Laboratory Medicine, NIH , Bethesda, Maryland, USA.
R MercadoDepartment of Laboratory Medicine, NIH , Bethesda, Maryland, USA.
W WangSystems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH , Bethesda, Maryland, USA.
M ChungSystems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH , Bethesda, Maryland, USA.
D RuchnewitzInstitute for Biological Physics, University of Cologne , Cologne, Germany.ORCID 0000-0001-5740-6958
M I SamanovicDepartment of Medicine, New York University Langone Vaccine Center , New York, New York, USA.
M J MulliganDepartment of Medicine, New York University Langone Vaccine Center , New York, New York, USA.
M LässigInstitute for Biological Physics, University of Cologne , Cologne, Germany.
M LukszaDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai , New York, New York, USA.
S DasDepartment of Laboratory Medicine, NIH , Bethesda, Maryland, USA.ORCID 0000-0002-2246-7942
D GreshamDepartment of Biology, Center for Genomics and Systems Biology, New York University , New York, New York, USA.ORCID 0000-0002-4028-0364
E GhedinSystems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH , Bethesda, Maryland, USA.ORCID 0000-0002-1515-725X
New York University · USNational Institutes of Health · USNYU Langone Health · USUniversity of Cologne · DEIcahn School of Medicine at Mount Sinai · USSt. Jude Children's Research Hospital · US

Funding

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012UM1AI148574 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Angelica Cifuentes Kottkamp, Anoma Nellore · 2020 to 2026
$23.9M
INFECTIOUS DISEASES &BASIC MICROBIOLOGICAL MECHANISMST32AI007180 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEISER, JEFFREY NEAL · 1985 to 2022
$8.9M
Genomic profiling of influenza infections to identify biomarkers of disease severityZIAAI001323 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GHEDIN, ELODIE · 2020 to 2025
$8.0M
Determining factors of transmission and evolution of SARS-CoV-2 in populations at risk ZIAAI001324 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GHEDIN, ELODIE · 2020 to 2025
$2.7M
The Quantitative Biological Systems Training (QBIST) ProgramT32GM132037 · NIGMS · NEW YORK UNIVERSITY · PI David Gresham, Christine Vogel · 2019 to 2026
$2.3M
NIAID NIH HHS HHSN272201400008CNIAID NIH HHS T32 AI007180NIAID NIH HHS UM1 AI148574NIGMS NIH HHS T32 GM132037
6 · The paper itself

Abstract

High error rates of viral RNA-dependent RNA polymerases lead to diverse intra-host viral populations during infection. Errors made during replication that are not strongly deleterious to the virus can lead to the generation of minority variants. However, accurate detection of minority variants in viral sequence data is complicated by errors introduced during sample preparation and data analysis. We used synthetic RNA controls and simulated data to test seven variant-calling tools across a range of allele frequencies and simulated coverages. We show that choice of variant caller and use of replicate sequencing have the most significant impact on single-nucleotide variant (SNV) discovery and demonstrate how both allele frequency and coverage thresholds impact both false discovery and false-negative rates. When replicates are not available, using a combination of multiple callers with more stringent cutoffs is recommended. We use these parameters to find minority variants in sequencing data from SARS-CoV-2 clinical specimens and provide guidance for studies of intra-host viral diversity using either single replicate data or data from technical replicates. Our study provides a framework for rigorous assessment of technical factors that impact SNV identification in viral samples and establishes heuristics that will inform and improve future studies of intra-host variation, viral diversity, and viral evolution. IMPORTANCE When viruses replicate inside a host cell, the virus replication machinery makes mistakes. Over time, these mistakes create mutations that result in a diverse population of viruses inside the host. Mutations that are neither lethal to the virus nor strongly beneficial can lead to minority variants that are minor members of the virus population. However, preparing samples for sequencing can also introduce errors that resemble minority variants, resulting in the inclusion of false-positive data if not filtered correctly. In this study, we aimed to determine the best methods for identification and quantification of these minority variants by testing the performance of seven commonly used variant-calling tools. We used simulated and synthetic data to test their performance against a true set of variants and then used these studies to inform variant identification in data from SARS-CoV-2 clinical specimens. Together, analyses of our data provide extensive guidance for future studies of viral diversity and evolution.

Indexed as

COVID-19OrthomyxoviridaeVirusesHigh-Throughput Nucleotide SequencingHumansMutationSARS-CoV-2bioinformaticsgenomicsinfluenzaSARS-CoV-2

Identifiers

PMID37389439
PMCPMC10470513
OpenAlexW4382632591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.